Akili Interactive
Pediatric prescription digital therapeutics company known for EndeavorRx, the first FDA-authorized prescription video game; acquired by Virtual Therapeutics in 2024 for ~$34M.
Boston, MA
2011
$160M+
Virtual Therapeutics
Commercial Insurance, Self-Pay
What They Do
Akili built software-based cognitive treatments for attention and related neurological conditions, with pediatric ADHD as its best-known commercial wedge. Its lead product, EndeavorRx, was cleared through the FDA de novo pathway and sold into a fragmented reimbursement environment that pushed the company toward a mix of payer contracting, prescription workflows, and later direct-to-consumer experimentation.
Competitive Position
Akili became the highest-profile test case for pediatric digital therapeutics reimbursement. It competed less with traditional pediatric behavioral-health providers than with the structural limits of payer coverage, prescription adoption, and clinician workflow integration. Its eventual sale to Virtual Therapeutics for ~$34M is now a cautionary benchmark for category economics.
Funding Rounds
No funding rounds on record for this company.